NICE OKs Pharmaxis and Novartis drugs but not Forest's colistimethate in CF patients
This article was originally published in Scrip
Executive Summary
In a wave of developments for cystic fibrosis (CF), NICE, the health technology appraisal institute for England and Wales, has recommended Pharmaxis's Bronchitol (mannitol dry powder) as a treatment option and separately, Novartis's Tobi Podhaler (tobramycin dry powder for inhalation; DPI) for Pseudomonas lung infection in people with the disease.